Zeptide is a tirzepatide injection manufactured by Ferozsons and is available in Pakistan for the treatment of adults with type 2 diabetes. Tirzepatide is also associated with clinically significant weight reduction when combined with appropriate dietary changes, physical activity, and ongoing medical supervision.
Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism improves blood glucose control, reduces appetite, enhances insulin sensitivity, and slows gastric emptying.
Available Strengths
| Strength | Price (PKR) |
|---|---|
| 2.5 mg | 2,950 |
| 5 mg | 3,950 |
| 7.5 mg | 4,950 |
| 10 mg | 5,950 |
| 12.5 mg | 6,250 |
| 15 mg | 6,500 |
Recommended Dose Escalation
Treatment is generally initiated with 2.5 mg once weekly for four weeks.
The dose is then increased to 5 mg once weekly. If additional glucose lowering or weight reduction is required and the medication is well tolerated, the dose may be increased every four weeks to:
- 7.5 mg
- 10 mg
- 12.5 mg
- 15 mg
The injection should be administered on the same day each week.
Tirzepatide Price Comparison in Pakistan
| Strength | Zeptide (PKR) | Tirzee (PKR) |
|---|---|---|
| 2.5 mg | 2,950 | 4,000 |
| 5 mg | 3,950 | 6,000 |
| 7.5 mg | 4,950 | 7,500 |
| 10 mg | 5,950 | 10,000 |
| 12.5 mg | 6,250 | Not available |
| 15 mg | 6,500 | Not available |
At the time of writing, Zeptide is available in strengths ranging from 2.5 mg to 15 mg, allowing gradual dose escalation according to individual treatment requirements.
Potential Benefits
Clinical studies have shown that tirzepatide may:
- Lower HbA1c
- Improve fasting blood glucose
- Reduce appetite
- Support clinically meaningful weight loss
- Require only one injection each week
Individual results vary, and treatment response depends on adherence to lifestyle modifications and regular medical follow-up.
Possible Adverse Effects
The most commonly reported adverse effects occur during the first few weeks of therapy and are usually gastrointestinal.
These may include:
- Nausea
- Vomiting
- Abdominal discomfort
- Bloating
- Diarrhea
- Constipation
- Reduced appetite
Less common but potentially serious adverse effects include acute pancreatitis, severe allergic reactions, and gallbladder disease.
Tirzepatide should not be used during pregnancy and is not indicated for people with type 1 diabetes. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should discuss alternative treatment options with their physician.
Medical Assessment Before Starting Tirzepatide
Before initiating tirzepatide therapy, physicians generally assess:
- Blood glucose and HbA1c
- Kidney function
- Liver function when appropriate
- Body weight and body mass index
- Current diabetes medications
- Risk factors for adverse effects
Regular follow-up is recommended during dose escalation.
About the Author
Dr. Ahmed Farhan is an Internal Medicine specialist with a clinical focus on diabetes, obesity, metabolic disorders, and lifestyle medicine. His practice includes individualized treatment planning for patients receiving GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, together with nutrition and long-term metabolic care.
Disclaimer
This article is intended for educational purposes only and should not be considered a substitute for professional medical advice. Tirzepatide is a prescription medication and should only be used under the supervision of a qualified healthcare professional.
